QYJD Compound Preparation Promotes Rapid Postoperative Re... | NCT06766565

Status Module

Description Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Blank control group	No Intervention	Group1 There was no oral drug treatment before surgery. Patients were treated with anti-inflammatory and analgesic therapy postoperatively on a case-by-case basis.
QYJD Compound Preparation intervention group	Experimental	Group2 In the treatment group, the patients were orally treated with expelling blood stasis and detoxifying compound preparation for 4 days before thoracoscopic radical lung cancer surgery, 2 capsules (0.3g/capsule) at a time, 3 times a day, with lukewarm water, for a total of 4 days.Patients were treated with anti-inflammatory and analgesic therapy postoperatively on a case-by-case basis.	Drug: QYJD Compound Preparation

Interventions

Name	Type	Description	Arm Group Labels	Other Names
QYJD Compound Preparation	Drug	The intervention group was treated with 2 capsules (g) of expelling stasis and QYJD compound preparation orally for 4 days before thoracoscopic radical surgery for lung cancer, 3 times a day. The blank control group had no oral drug treatment before surgery.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Rapid rehabilitation indexes	the number of days of postoperative chest drain retention	15 days
Rapid rehabilitation indexes	postoperative pain VAS scores	1 week
Rapid rehabilitation indexes	six-minute walking experiments	7 day
Laboratory indicators of inflammation	including white blood cell count, neutrophil count, lymphocyte count, platelet count, NLR, PLR	through study completion, an average of 1 year

Eligibility Module

Eligibility Criteria

Study Population Patients diagnosed with early-stage non-small cell lung cancer in accordance with the Primary Lung Cancer Diagnosis and Treatment Guidelines (2022 Edition) issued by the National Health and Health Commission and the TNM staging criteria of the 8th edition of the International Association for the Study of Lung Cancer (IASLC).

Inclusion criteria:

Patients with (a) no contraindications to surgery, early stage NSCLC diagnosed by postoperative pathology, and clinical stage I-IIIA; (b) aged 18-80 years old, with KPS score ≥60; (c) with expected survival of more than 3 months; (d) with no history of smoking; (e) with no previous underlying lung diseases such as bronchiectasis, bronchial asthma, or COPD; (f) without neoadjuvant chemotherapy; (g) with no previous treatment with neoadjuvant chemotherapy; (h) with no previous treatment with neoadjuvant chemotherapy; (i) with no previous treatment with bronchodilatation, bronchial asthma, or COPD; (j) with no previous treatment with neoadjuvant chemotherapy. (f) No neoadjuvant chemotherapy; (g) No history of other systemic malignancies; (h) Sufficient fresh tumor tissue specimens are available.
Participants are willing to participate in this study and comply with the study plan;
Participants or legally authorized representatives were able to provide written informed consent approved by the ethical review board managing the site.

Exclusion Criteria:

the presence of malignant tumors or metastatic foci in other parts of the body;
the combination of other organic diseases;
psychiatric disorders or communication disorders;
lung infections, systemic hematologic diseases, immune system diseases;
bronchodilatation, bronchial asthma, or chronic obstructive pulmonary disease and other underlying lung diseases;
within the past month, there are antibiotics, immunosuppressive drugs, hormones, probiotics, as well as any those who have taken antibiotics, immunosuppressants, hormones, probiotics, and any form of traditional Chinese medicine or proprietary Chinese medicine within the past month;
Those who have a history of smoking;
Those who have a history of occupational or environmental exposure to dust, mines, or asbestos.